Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
Authors' conclusion
Dulaglutide 1.5 mg reduced SBP and pulse pressure in people with T2D across the placebo-controlled trials in the AWARD program. While up to one third of the effect of dulaglutide 1.5 mg on SBP and pulse pressure was due to weight reduction, the majority was independent of weight. A greater understanding of the pleotropic effects of GLP-1 RA that contribute to reduction in blood pressure could support developing future approaches for treating hypertension.
Study context
- Population
- Participants with T2D in placebo-controlled trials of the AWARD program5 RCTs
- Comparison
- Dulaglutide 1.5 mg vs placebo
- Outcome
- Weight-dependent and weight-independent effects of dulaglutide 1.5 mg treatment in participants with T2D
- Follow-up
- ≈6 months
Methodological detailsindirect comparison (AWARD-11, dulaglutide 4.5 mg vs 1.5 mg)
- Indirect comparison (AWARD-11, dulaglutide 4.5 mg vs 1.5 mg)
Pooled result
As reported in the abstract
Total treatment effect
- 2.6 mmHg
95% CI - 3.8, - 1.5P < 0.001
Change from baseline in systolic blood pressure (SBP) (placebo-adjusted)
Weight-dependent effect
- 0.9 mmHg
95% CI - 1.4, - 0.5P < 0.001
36% of total effect
Weight-independent effect
- 1.5 mmHg
95% CI - 2.6, - 0.3P = 0.01
64% of total effect
Further pooled results
| Outcome | Total treatment effect (mmHg) (95% CI) | P value |
|---|---|---|
| Pulse pressure14% weight-dependent, 86% weight-independent | - 2.5 (- 3.5, - 1.5) | P < 0.001 |
Diastolic blood pressure (DBP)
- Limited impact of dulaglutide on DBP, with only a small weight-mediated effect
Dulaglutide 4.5 mg vs 1.5 mg (AWARD-11)
- Dulaglutide 4.5 mg reduced SBP and pulse pressure beyond dulaglutide 1.5 mg, primarily weight mediated
- Indirect comparison
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →